lobbying_activities: 2874529

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2874529	cb22e4fe-e598-4ddf-b15b-2c295dd0297e	Q3	FAEGRE DRINKER BIDDLE & REATH LLP	12631	NATIONAL ASSOCIATION OF BOARDS OF PHARMACY	2022	third_quarter	PHA	Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act; S. 2796/H.R. 2985 Rural Opioid Abuse Prevention Act; H.R. 2355 Opioid Prescription Verification Act.	Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE	30000		0	0	2022-10-19T10:30:30-04:00